Page 13 - Pharma Sector

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Booster shot as India's pharma market grew 8.4% in FY25: Pharmarack

Augmentin remains top-selling medicine brand at Rs 816 crore sales

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Pharma companies likely to pass on costs in US as fresh levy looms

Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors

Higher tariffs may significantly dent profits of pharma companies

Companies such as Sun Pharma which have a significant specialty portfolio could be less impacted than Indian peers in the US market given lower competition in niche segments

Emcure arm Tillomed acquires Manx Pharma portfolio for Rs 218.67 cr

The deal includes the purchase of product dossiers, marketing authorisations, intellectual property, and inventory

Trump says tariffs on chips and pharma imports to be announced soon

President Trump has said tariffs on pharmaceutical and semiconductor imports will be announced shortly, as the US imposes a 27% duty on all imports from India

Here's why Medicamen Biotech shares skyrocketed 12% in trade on April 3

Medicamen Biotech stock rose following the announcement of a strategic partnership with XGX Pharma, a European company.

Pharma, semiconductors escape Trump's tariffs. See full exemption list here

Pharmaceuticals, semiconductors, and other goods are exempt from Trump's tariffs, as the White House releases a full list ahead of the April 5 implementation

India's pharma industry gets relief from Trump's reciprocal tariff

US President says India imposes 52% tariff on American imports and engages in currency manipulation and non-tariff barriers

US businesses get ready for more pain as Trump rolls out reciprocal tariffs

The US will now impose a 10 per cent baseline tariff on all imports to the country effective April 5 and higher duties on several of its biggest trading partners

Drug prices may rise in US if Indian pharma firms pass on Trump's tariff

The US administration has not made announcements yet on sector-specific tariffs

'Scenario building' in Indian Pharma Inc ahead of US tariff announcement

Pharmaceutical products have been on the radar of US President Donald Trump, who has indicated that tariffs of up to 25 per cent could be imposed on this category

US tariffs may hit agri, machinery, pharma, electrical sectors: Experts

Goods from sectors, including agriculture, precious stones, chemicals, pharma, medical devices, electricals, and machinery may get impacted if the US will go ahead with imposing reciprocal tariffs on Indian products, according to experts. They said that these sectors could face additional customs duties from the Trump administration because of the high tariff differential or gap, which is the difference between the import duties imposed by the US and India on a product. At the broad sector level, the potential tariff gaps between India and the US vary across the sectors. The gap is 8.6 per cent for chemicals and pharmaceuticals; 5.6 per cent for plastics; 1.4 per cent for textiles and clothing; 13.3 per cent for diamonds, gold, and jewellery; 2.5 per cent for iron, steel, and base metals; 5.3 per cent for machinery and computers; 7.2 per cent for electronics; and 23.1 per cent for automobiles and auto components. "The higher the tariff gap, the worse affected a sector could be," an

Agilus Diagnostics lowers marketing spend 2 years after rebranding

In FY25, an additional Rs 50 crore was spent on marketing over and above the usual budget

Pharmaceutical growth cure lies in CDMOs' resilience to market ailments

They get growth Rx from outsourcing, with fewer Trump tariff side effects

Health ministry flags 47 drugs as 'not of standard quality' in February

The Central Drugs Laboratories in its monthly drug alert for February found 47 drug samples manufactured by various firms to be "not of standard quality (NSQ)", health ministry officials said on Friday. Further, the State Drugs Testing Laboratories have identified 56 drug samples as NSQ, they said. According to routine regulatory surveillance activity, the list of NSQ drugs is displayed on the Central Drugs Standard Control Organisation (CDSCO) portal every month. Identification of drug samples as NSQ is done based on the failure of the drug sample in one or the other specified quality parameters, the officials said. The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns about the other drug products available in the market, an official said. In February 2024, one drug sample from West Bengal was identified as spurious and made by unauthorised manufacturer using a brand name owned by another company. The .

Entvin AI raises Rs 5 crore in first funding round from Y Combinator

With this funding, Entvin plans to expand its artificial intelligence capabilities and accelerate customer acquisition

Centre disbursed Rs 14,020 crore for 10 sectors so far under PLI schemes

The government has disbursed Rs 14,020 crore under Production-Linked Incentive schemes for ten sectors, including electronics and pharma, since the launch of the support measure to boost domestic manufacturing, an official statement said on Saturday. In 2021, the government announced Production-Linked Incentive (PLI) schemes for 14 sectors like telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell batteries, drones, and pharma, with an outlay of Rs 1.97 lakh crore. "The incentive amount of around Rs 14,020 crore disbursed under PLI schemes for 10 sectors," the commerce and industry ministry said. These sectors are large-scale electronics manufacturing, IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom and networking products, food processing, white goods, automobiles and auto components and drones. Individual cases have been approved over a

Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a medication used in the treatment of low blood pressure and low heart rate in children. Piramal Critical Care (PCC) has secured the commercialisation rights for Neoatricon, the first paediatric strength solution for infusion of Dopamine Hydrochloride, for the EU, the UK, and Norway markets, Piramal Pharma said in a regulatory filing. PCC would be responsible for distributing Neoatricon in these regions, it added. Developed by BrePco Biopharma, Neoatricon is an age-appropriate, ready-to-use, sterile solution for infusion of Dopamine Hydrochloride. It is available in a concentration of 1.5mg/mL in a 30 mL vial and a higher strength containing 4.5mg/mL in a 50 mL vial. Currently, there are no approved Dopamine Hydrochloride formulations specifically indicated for use in neonates, infants, or ..